Repare Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de Repare Therapeutics disminuyan en un 22.7% al año, mientras que se espera que sus ingresos anuales crezcan en un 5.3% al año. Se prevé que el BPA disminuya en un 15.3% por año. Se espera que la rentabilidad financiera sea de -69.7% en 3 años.
Información clave
-22.7%
Tasa de crecimiento de los beneficios
-15.3%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.5% |
| Tasa de crecimiento de los ingresos | 5.3% |
| Rentabilidad financiera futura | -69.7% |
| Cobertura de analistas | Good |
| Última actualización | 12 Jun 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01
Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Nov 19Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 44 | -154 | -130 | -125 | 5 |
| 12/31/2025 | 11 | -168 | -128 | -127 | 6 |
| 12/31/2024 | 60 | -101 | -64 | -63 | 7 |
| 3/31/2024 | 98 | -46 | -85 | -83 | N/A |
| 12/31/2023 | 51 | -94 | -129 | -127 | N/A |
| 9/30/2023 | 56 | -97 | -128 | -129 | N/A |
| 6/30/2023 | 167 | -3 | -8 | -8 | N/A |
| 3/31/2023 | 137 | -29 | -2 | -1 | N/A |
| 12/31/2022 | 132 | -29 | 0 | 0 | N/A |
| 9/30/2022 | 121 | -26 | 7 | 9 | N/A |
| 6/30/2022 | 8 | -132 | -114 | -112 | N/A |
| 3/31/2022 | 8 | -120 | -103 | -102 | N/A |
| 12/31/2021 | 8 | -107 | -87 | -86 | N/A |
| 9/30/2021 | 1 | -94 | -81 | -78 | N/A |
| 6/30/2021 | 1 | -77 | -69 | -65 | N/A |
| 3/31/2021 | 0 | -62 | -14 | -11 | N/A |
| 12/31/2020 | 0 | -53 | -8 | -6 | N/A |
| 9/30/2020 | N/A | -46 | -4 | -2 | N/A |
| 6/30/2020 | N/A | -40 | 11 | 12 | N/A |
| 3/31/2020 | N/A | -35 | -32 | -31 | N/A |
| 12/31/2019 | N/A | -27 | -20 | -18 | N/A |
| 12/31/2018 | N/A | -14 | -13 | -13 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que RPTX siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que RPTX siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que RPTX siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (5.3% al año) de RPTX crezcan más despacio que el mercado de US (8.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 5.3% al año) de RPTX crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: RPTX se prevé que no sea rentable en 3 años.